Marizomib

Cancer

CelgeneSmall moleculePhase 1Dormant

CC

46/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 37/ 100
Competitive Position: 73/ 100

Competitive context

1380 Active assets in the Cancer cohort.

Asset / Sponsor	Phase	Rating
Nabiximols Jazz Pharmaceuticals	Phase 3	BBB
Pyridoxol M.D. Anderson Cancer Center	Phase 4	BB
Rivoceranib Jiangsu HengRui Medicine Co., Ltd.	Phase 4	BB
Desflurane Peter MacCallum Cancer Centre, Australia	Phase 4	BB
Propofol Hong Kong Children's Hospital	Phase 4	BB

View all 50 →

Same molecule, other indications

Marizomib is also rated in:

malignant gliomaDormant

BB

Indicative · Phase 2

68 / 100

glioblastomaDormant

B

Indicative · Phase 3

63 / 100

plasma cell myelomaActive

CCC

Indicative · Phase 2

53 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.